Metamark Genetics Inc., of Cambridge, Mass., reported that a prostate cancer study published in Nature described the identification of a key tumor suppressor of prostate cancer progression in mice and humans, and revealed four markers that are predictive of biochemical recurrence and lethal metastasis in human prostate cancer.